Rabinowitz Matthew sold $16.4M of NTRA
Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 50,000 shares of Natera, Inc. (NTRA) at an average of $327.97 ($325.01–$329.62, $16.40M total) across 6 trades on 2026-09-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public report of this transaction, making it a primary source of new information.
Market read
Insider sell of this size may prompt short‑term price pressure, but the pre‑arranged nature tempers the signal.
What to watch
The 10b5‑1 plan indicates pre‑planned execution, reducing the informational weight of the sale.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑scheduled sales.
Ticker impact
Executive Chairman Matthew Rabinowitz sold 50,000 shares for $16.4M via a 10b5‑1 plan, reducing his stake to 2,225,394 shares.
Possible modest downside pressure over the next few days.
A $16M sale by a top executive is material and disclosed first via Form 4; markets often react negatively to sizable insider disposals.
Market effects
Minimal; biotech sector may see slight sentiment drag from insider sell.
U.S. market only; no broader regional effect.
Low; limited to Natera investors.
Counterpoint
The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.
Key entities
- ExecutiveMatthew Rabinowitz
Executive Chairman of Natera, Inc.
- CompanyNatera, Inc.
Genomics testing company listed on NASDAQ.
